Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study.

Ma, Yi-Ming; Cheng, Shu-Xia; Zhang, Ming-Chuan; Zhang, Hui-Ying; Gu, Jun-Jiao; Zhao, Pan-Pan; Ge, Hong

Ma, Yi-Ming; Cheng, Shu-Xia; Zhang, Ming-Chuan; Zhang, Hui-Ying; Gu, Jun-Jiao; Zhao, Pan-Pan; Ge, Hong.

Afiliación

Ma YM; Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Cheng SX; Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Zhang MC; Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Zhang HY; Department of Oncology, The First Affiliated Hospital of Henan University, Kaifeng, China.
Gu JJ; Department of Oncology, Huaihe Hospital of Henan University, Kaifeng, China.
Zhao PP; Department of Gynecologic, The First Affiliated Hospital of Henan University of Science and Technology, Jiaozuo, China.
Ge H; Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Ann Transl Med ; 10(20): 1107, 2022 Oct.

Article en En | MEDLINE | ID: mdl-36388810

Palabras clave

Cervical cancer; adverse events; chemotherapy; prognostic factors; programmed cell death protein 1 inhibitor (PD-1 inhibitor)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google